Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.

672 F. Supp. 2d 596, 2009 U.S. Dist. LEXIS 114819, 2009 WL 4668579
CourtDistrict Court, S.D. New York
DecidedDecember 9, 2009
Docket08 Civ. 7422(VM)
StatusPublished
Cited by34 cases

This text of 672 F. Supp. 2d 596 (Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Varghese v. China Shenghuo Pharmaceutical Holdings, Inc., 672 F. Supp. 2d 596, 2009 U.S. Dist. LEXIS 114819, 2009 WL 4668579 (S.D.N.Y. 2009).

Opinion

DECISION AND ORDER

VICTOR MARRERO, District Judge.

Lead plaintiff William R. Bennett (“W. Bennett”) and Named Plaintiff Chia-Yiu Maa (“Maa”) (collectively “Plaintiffs”) filed a consolidated amended complaint in this putative class action dated February 9, 2009 (the “Amended Complaint”), naming as defendants China Shenghuo Pharmaceutical Holdings, Inc. (“CSP”); Lan’s International Medicine Investment Co., Limited (“LIMI”); as well as individual defendants Gui Hua Lan (“Gui”) and Qiong Hua Gao (“Qiong”) (collectively “CSP Defendants”). Plaintiffs also name CSP’s independent auditor, Hansen, Barnett & Maxwell, P.C. (“HB & M”). Plaintiffs assert claims under § 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. § 78j(b) (“§ 10(b)”); Rule 10b-5 promulgated

thereunder, 17 C.F.R. § 240.10b-5 (“Rule 10b—5”); and § 20(a) of the Exchange Act, 15 U.S.C. § 78t(a) (“§ 20(a)”). Plaintiffs bring these claims on behalf of themselves and all other persons or entities who purchased CSP securities (the “Class”) during the period August 16, 2007 through April 20, 2008 (the “Class Period”). CSP Defendants and HB & M both move to dismiss Plaintiffs’ claims pursuant to Federal Rule of Civil Procedure 12(b)(6) (“Rule 12(b)(6)”) for failure to state a claim upon which relief can be granted. For the reasons stated below, CSP Defendants’ motion is DENIED, and HB & M’s motion to dismiss is DENIED.

I. BACKGROUND 1

A. PARTIES

Defendant CSP, a Delaware corporation with headquarters in China, is engaged in the research, development, manufacture, and marketing of pharmaceuticals, nutritional supplements, and cosmetic products. Defendant LIMI controlled 77% of CSP’s stock during the Class Period. Defendant Gui has served as CSP’s chief executive officer and chairman of the board since 1995. Gui is also president and chairman of LIMI, and as of April 2008, owned more than 62% of LIMI’s outstanding shares. Defendant Qiong served as CSP’s chief financial officer from January 2005 until she was removed in November 2008.

Defendant HB & M is a regional public accounting firm that served as CSP’s outside auditor during the Class Period.

Bennett purchased more than 26,000 shares of CSP common stock on October 25, 2007. Maa purchased a total of 40,000 *602 shares of CSP common stock during the Class Period. Maa made his first purchase on November 29, 2007 and his last purchase on July 2, 2008.

B. FACTUAL ALLEGATIONS

The Class Period begins on August 16, 2007, about two months after CSP began trading on the American Stock Exchange (“AMEX”), and when CSP filed its second quarter Form 10-QSB with the SEC (“2nd Quarter 2007 Form 10-QSB”). The Class Period includes CSP’s third quarter filing with the SEC (“3rd Quarter 2007 Form 10-QSB”), the 2007 fourth quarter and full year filings (“Fiscal Year and 4th Quarter 2007 Form 10-KSB”), as well as the 2008 first quarter filing (“1st Quarter 2008 Form 10-Q”). The Class Period concludes August 20, 2008, when CSP announced that its financial statements throughout the Class Period could no longer be relied upon and would have to be restated.

The 2nd Quarter 2007 Form 10-QSB, filed August 16, 2007, included a disclosure that CSP’s internal controls “had significant deficiencies that caused [CSP’s] controls and procedures to be ineffective.” (Amended Complaint ¶ 31.) CSP reassured investors that it was in the process of “remediating] these deficiencies through improving supervision, education, and training of CSP’s accounting staff,” and that the “remedial steps that [CSP takes] will address the conditions identified by [Gui] as significant deficiencies in [its] disclosure controls and procedures.” (Id.) The 2nd Quarter 2007 Form 10-QSB included Sarbanes-Oxley Act (“SOX”) certifications signed by Qiong and Gui, who attested that the filing did not contain “any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading” and that the financial statements “fairly present in all material respects the financial condition, results of operations and cash flows” of CSP. (Id. ¶ 30.)

CSP made nearly identical disclosures on the 3rd Quarter 2007 Form-QSB, filed November 15, 2007, and certified by Qiong and Gui.

On March 31, 2008, CSP filed its Fiscal Year and 4th Quarter 2007 Form 10-KSB, which reported CSP’s 2007 net income as $4,016,640, earnings per share as $0.21, and general and administrative expenses as $4,935,754. HB & M represented in the Fiscal Year and 4th Quarter Form 10-KSB that CSP’s financial results were presented in compliance with Generally Accepted Accounting Principles (“GAAP”) and that HB & M’s audits were conducted in accordance with Generally Accepted Auditing Standards (“GAAS”). Like the previous filings, the Fiscal Year and 4th Quarter 2007 Form 10-KSB included SOX certifications signed by Gui and Qiong.

On April 1, 2008, CSP issued a press release regarding the 2007 financial results (the “April 2008 Press Release”). The April 2008 Press Release stated that CSP had “implemented internal controls to comply with [SOX]” and that “beginning late in 2007, [CSP] implemented an internal control system, which will help ... to enhance [its] operating efficiency and reduce business risks.” (Id. ¶ 41.)

CSP filed its 1st Quarter 2008 Form 10-Q on May 20, 2008. In the 1st Quarter 2008 Form 10-Q, CSP claimed that its financial statements were prepared in accordance with GAAP. CSP also reported that it was in the process of addressing internal control weaknesses “by improving supervision, education, and training of [its] accounting staff.” (Id. 1Í48.) CSP repeated that the “remedial steps that [CSP] take[s] will address the conditions identified by [Gui] as significant deficiencies in *603 [its] disclosure controls and procedures.” (Id. ¶ 46.)

On August 20, 2008, CSP announced that its financial statements throughout the Class Period could no longer be relied upon and would have to be restated. At that time, CSP anticipated that it would have to restate its financial statements for its fiscal periods ending June 30, 2007, September 30, 2007, December 30, 2007, and March 31, 2008. On the day of the announcement, CSP’s stock fell from $2.33 per share to $1.89 per share. Shortly thereafter, AMEX halted CSP’s trading privileges.

On September 12, 2008, CSP filed a Form 8-K/A confirming that investors should not rely on CSP’s statements issued throughout the Class Period.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

O'MEARA v. SHIFT4 PAYMENTS, INC.
E.D. Pennsylvania, 2024
Xu v. Gridsum Holding Inc.
S.D. New York, 2021
Barilli v. Sky Solar Holdings, Ltd.
389 F. Supp. 3d 232 (S.D. Illinois, 2019)
Thomas Martone v. Walter Robb, III
902 F.3d 519 (Fifth Circuit, 2018)
In re Sunedison, Inc.
300 F. Supp. 3d 444 (S.D. Illinois, 2018)
Godinez v. Alere Inc.
272 F. Supp. 3d 201 (D. Massachusetts, 2017)
Fresno County Employees' Retirement Ass'n v. comScore, Inc.
268 F. Supp. 3d 526 (S.D. New York, 2017)
In re Eletrobras Securities Litigation
245 F. Supp. 3d 450 (S.D. New York, 2017)
In re Vivendi Universal, S.A. Securities Litigation
123 F. Supp. 3d 424 (S.D. New York, 2015)
In re Petrobras Securities Litigation
116 F. Supp. 3d 368 (S.D. New York, 2015)
Royal Park Investments SA/NV v. HSBC Bank USA, National Ass'n
109 F. Supp. 3d 587 (S.D. New York, 2015)
In re ITT Educational Services, Inc. Securities Litigation
34 F. Supp. 3d 298 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
672 F. Supp. 2d 596, 2009 U.S. Dist. LEXIS 114819, 2009 WL 4668579, Counsel Stack Legal Research, https://law.counselstack.com/opinion/varghese-v-china-shenghuo-pharmaceutical-holdings-inc-nysd-2009.